The Company operates Beauty Clinics specializing in Aesthetic Skin, Body and Weight Management, Plastic Surgery, and Wellness based on modern medical principles that are approved by the US FDA.
| 3M26 | 3M25 | 2025 | 2024 |
|---|
| Revenues | 819.58 | 3,580.03 | 3,008.95 | |
| Expenses | 706.71 | 3,092.64 | 2,594.13 | |
| Net Profit (Loss) | 84.80 | 363.70 | 322.19 |
| Assets | 3,302.63 | 3,339.26 | 3,118.14 | |
| Liabilities | 1,480.88 | 1,557.96 | 1,401.21 | |
| Shareholders' Equity | 1,801.72 | 1,773.38 | 1,716.93 |
| Operating | 210.37 | 660.77 | 551.98 | |
| Investing | 86.77 | -157.61 | 15.79 | |
| Financing | -11.78 | -436.36 | -428.39 |
| EPS (Baht) | 0.39 | 1.65 | 1.46 | |
| GP Margin (%) | 50.76 | 50.51 | 51.71 | |
| NP Margin (%) | 10.35 | 10.17 | 10.71 | |
| D/E Ratio (x) | 0.81 | 0.87 | 0.82 | |
| ROE (%) | 18.53 | 20.84 | 18.84 | |
| ROA (%) | 13.60 | 15.10 | 13.91 |
Vision
To be a leader on an international scale for Aesthetic, Plastic Surgery, and Wellness center through the use of medical and innovative services, aiming to be the best beauty provider in South East Asia
Key Strategic Highlights
- Strengthen further Brand Equity
- Optimize the Surgery Center
- Monetize the macro Health and Wellness trend
- Prioritize Innovation and Safety to ensure results
- Expand coverage of THE KLINIQUE, L.A.B.X, L'CLINIC, ACNE LABS CLINIC and KLINIQ WELLNESS SPA
As of 31 March 2026, the Company has a total of 82 branches
- 45 THE KLINIQUE branches
- 26 L.A.B.X branches
- 1 THE KLINIQUE SURGERY CENTER
- 8 L' CLINIC branches
- 1 ACNE LABS CLINIC branch
- 1 KLINIQ WELLNESS SPA branches
The four service departments of the Company’s medical clinics and surgery center are Aesthetic Skin, Body & Weight Management, Plastic Surgery, and Wellness.
In Q1/2026, the Company’s total revenue from sales and services was THB 1,086.26 million, increased of 33.5% from the same period in 2025 because of expanding 9 branches to reach more customers group, investing in medicines and medical equipment to provide a wide range of services, promotions for the target customers and the growth of revenue from all brands.
In Q1/2026, the Company opened new branches as follows;
- 3 new L'CLINIC branches at Seacon Bangkae, Central Rama 2 and Central Ladprao.
- Risks of Competition in the Aesthetics Business
The Company adopts a strategy to differentiate itself. This involves building a memorable brand for consumers, offering comprehensive services with the latest innovations from Europe and the USA, enhancing staff capabilities to meet consumer demands, and expanding its branch network. By establishing branches nationwide, the Company aims to meet consumer needs more effectively and make its services readily accessible to consumers.
- Risks from Changes in Treatment Technology
The Company prioritizes and emphasizes quality, analysis, and the provision of treatment services to patients using efficient and safe medical equipment, certified by the US FDA and the Thai FDA. This certification is deemed the best standard of safety. The Company continuously invests in updating its medical tools and equipment. However, based on operational data since 2009, the Company has observed that the average lifecycle of technological changes in medical tools and equipment spans approximately 5 to 12 years. The medical tools the Company currently employs can still deliver effective treatments. Nonetheless, newer technology in medical equipment often comes at a higher cost, which could potentially affect the investment's value. To mitigate the impacts from these technological shifts, the Company has implemented a series of steps for approving various investments. Policies for medical equipment procurement have been established, including an analysis of the return on investment period for significant medical tools. An annual medical equipment purchasing budget is prepared, requiring approval from the Company's Board of Directors.
- The Golden Records Award: Highest Achievement APAC Awards for Ultherapy Transducer
- The Golden Records Award: Highest Achievement APAC Awards for Merz Aesthetics Portfolio
- Global Health Aesthetics Awards 2025: Medical Aesthetic and Surgical Centre of the Year in Asia-Pacific
- The Thailand Number One Legendary Award for Ultherapy Transducer Usage
- Etc.
| as of 31/03/26 | KLINIQ | HELTH | SET |
|---|---|---|---|
| P/E (X) | 14.22 | 16.49 | 16.56 |
| P/BV (X) | 2.92 | 2.32 | 1.36 |
| Dividend yield (%) | 6.17 | 5.14 | 4.41 |
| 31/03/26 | 30/12/25 | 30/12/24 | |
|---|---|---|---|
| Market Cap (MB) | 5,170.00 | 4,708.00 | 7,150.00 |
| Price (B/Share) | 23.50 | 21.40 | 32.50 |
| P/E (X) | 14.22 | 13.39 | 23.72 |
| P/BV (X) | 2.92 | 2.83 | 4.42 |